Jacques P. Brown
#166,660
Most Influential Person Now
Rheumatologist, researcher and professor at Université Laval
Jacques P. Brown's AcademicInfluence.com Rankings
Jacques P. Brownphilosophy Degrees
Philosophy
#9839
World Rank
#13453
Historical Rank
Logic
#6797
World Rank
#8346
Historical Rank
Download Badge
Philosophy
Why Is Jacques P. Brown Influential?
(Suggest an Edit or Addition)Jacques P. Brown's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. (1999) (2436)
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (2010) (1365)
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (1998) (1129)
- The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women (2007) (1115)
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (2015) (959)
- Intravenous zoledronic acid in postmenopausal women with low bone mineral density. (2002) (868)
- Romosozumab in postmenopausal women with low bone mineral density. (2014) (801)
- 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. (2002) (782)
- A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy (2013) (780)
- Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. (2000) (748)
- Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. (1997) (676)
- SERUM BONE GLA-PROTEIN: A SPECIFIC MARKER FOR BONE FORMATION IN POSTMENOPAUSAL OSTEOPOROSIS (1984) (673)
- Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial (2009) (606)
- Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. (2002) (559)
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. (2017) (535)
- A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX (2016) (467)
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension (2018) (434)
- Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy (2010) (409)
- Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. (2005) (403)
- Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study (2009) (395)
- Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. (1998) (385)
- The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis (2002) (329)
- The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. (2004) (308)
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (2017) (262)
- The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada (2001) (252)
- The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension (2013) (240)
- Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies (2010) (224)
- Research Notes: The Canadian Multicentre Osteoporosis Study (CaMos): Background, Rationale, Methods (1999) (218)
- Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. (2001) (216)
- A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee (2011) (201)
- Bone turnover markers in the management of postmenopausal osteoporosis. (2009) (198)
- A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone (1999) (179)
- High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group (2013) (179)
- Bone strength: the whole is greater than the sum of its parts. (2006) (176)
- The care gap in diagnosis and treatment of women with a fragility fracture (2007) (173)
- Bisphosphonate Associated Osteonecrosis of the Jaw (2008) (173)
- Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. (2017) (172)
- Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. (2008) (171)
- Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos (2011) (171)
- Cancer treatment-induced bone loss in breast and prostate cancer. (2008) (167)
- The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study (2009) (167)
- Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. (2004) (165)
- Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates (2016) (161)
- The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women (2002) (157)
- Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study (2010) (154)
- Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension (2011) (152)
- The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos) (2003) (152)
- Recommendations for bone mineral density reporting in Canada. (2005) (152)
- Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study (1998) (150)
- Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate (2006) (147)
- Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. (2014) (143)
- Sequestosome 1: Mutation Frequencies, Haplotypes, and Phenotypes in Familial Paget's Disease of Bone (2006) (142)
- The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study (2008) (138)
- Risk factors for low BMD in healthy men age 50 years or older: a systematic review (2009) (136)
- The burden of illness of osteoporosis in Canada (2012) (135)
- Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial (2013) (133)
- Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. (2014) (133)
- Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial (2010) (125)
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study (2018) (124)
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? (2011) (123)
- Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. (2004) (117)
- A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years (2011) (111)
- Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass (2017) (107)
- Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. (2011) (100)
- Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database (2003) (99)
- Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab (2013) (98)
- Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis (2004) (90)
- Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. (2010) (87)
- Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. (2007) (86)
- The current economic burden of illness of osteoporosis in Canada (2016) (84)
- Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis (2010) (82)
- Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis (2015) (79)
- The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. (2009) (78)
- Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. (1987) (77)
- Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. (2007) (77)
- Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos) (2005) (75)
- A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture (2015) (75)
- The Natural Progression of Health-Related Quality of Life: Results of a Five-Year Prospective Study of SF-36 Scores in a Normative Population (2006) (74)
- Vertebral Fracture Status and the World Health Organization Risk Factors for Predicting Osteoporotic Fracture Risk (2009) (73)
- Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. (2012) (73)
- Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment (2019) (73)
- Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis (2007) (72)
- Osteoporosis Canada 2010 Guidelines for the Assessment of Fracture Risk (2011) (72)
- Canadian Consensus Conference on osteoporosis, 2006 update. (2006) (72)
- Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass (2017) (72)
- Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross‐Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos) (2018) (70)
- Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis (2007) (67)
- Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off‐treatment biopsy study (2011) (66)
- Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists (2016) (64)
- Algorithms can be used to identify fragility fracture cases in physician-claims databases (2012) (63)
- Ten-year incident osteoporosis-related fractures in the population-based Canadian Multicentre Osteoporosis Study - comparing site and age-specific risks in women and men. (2015) (60)
- Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study (2014) (58)
- Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis (2018) (57)
- Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). (2013) (57)
- The Radiology of Osteoporotic Vertebral Fractures Revisited (2019) (55)
- Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data (2016) (55)
- Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. (2010) (55)
- ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor (2016) (53)
- Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement. (2004) (52)
- Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension (2014) (52)
- Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study (2011) (51)
- Risedronate, a Highly Effective, Short-Term Oral Treatment for Paget's Disease: A Dose-Response Study (1999) (51)
- Loss of health related quality of life following low-trauma fractures in the elderly (2016) (51)
- Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. (2016) (50)
- The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. (2009) (50)
- Trends in hip fracture rates in Canada: An age‐period‐cohort analysis (2013) (49)
- Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. (2004) (49)
- Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis (2016) (49)
- Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee (2013) (48)
- Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study (2018) (48)
- Changes to Osteoporosis Prevalence According to Method of Risk Assessment (2006) (47)
- Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate (2014) (47)
- Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis (2006) (47)
- A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. (1999) (47)
- Intravenous zoledronic acid in postmenopausal women with low bone mineral density (2003) (46)
- Standards for performing DXA in individuals with secondary causes of osteoporosis. (2006) (46)
- Evaluation of easily measured risk factors in the prediction of osteoporotic fractures (2005) (45)
- Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000. (2001) (45)
- Determinants of health-related quality of life in women with vertebral fractures (2005) (44)
- Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet (2011) (44)
- A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial (2016) (44)
- Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta. (2011) (43)
- Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. (2000) (42)
- Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression (2019) (41)
- Emerging strategies and therapies for treatment of Paget’s disease of bone (2011) (39)
- Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. (2008) (39)
- Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women (2012) (39)
- Health-related Quality of Life in Canadian Adolescents and Young Adults: Normative Data Using the SF-36 (2009) (38)
- Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate (2003) (38)
- Novel SQSTM1 mutations in patients with Paget's disease of bone in an unrelated multiethnic American population. (2011) (37)
- Multisite quantitative ultrasound for the prediction of fractures over 5 years of follow‐up: The Canadian Multicentre Osteoporosis Study (2013) (36)
- Stability of Normative Data for the SF-36 (2004) (35)
- The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial (2011) (35)
- Management of osteoporosis in men: an update and case example (2007) (34)
- Epidemiogenetic study of French families with Paget's disease of bone. (2012) (33)
- Fracture risk prediction: importance of age, BMD and spine fracture status (2013) (33)
- Fracture risk prediction: importance of age, BMD and spine fracture status (2013) (33)
- Sex-specific association between obesity and self-reported falls and injuries among community-dwelling Canadians aged 65 years and older (2017) (32)
- The 2002 Canadian bone densitometry recommendations: take-home messages. (2002) (31)
- NR4A1‐dependent Ly6Clow monocytes contribute to reducing joint inflammation in arthritic mice through Treg cells (2016) (30)
- Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. (2016) (30)
- Low urine pH and acid excretion do not predict bone fractures or the loss of bone mineral density: a prospective cohort study (2010) (29)
- Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. (2013) (29)
- Impact of Air Pollutants on Oxidative Stress in Common Autophagy-Mediated Aging Diseases (2015) (29)
- Assessment of femur geometrical parameters using EOS™ imaging technology in patients with atypical femur fractures; preliminary results. (2016) (29)
- Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. (2009) (25)
- Osteoporotic fractures and obesity affect frailty progression: a longitudinal analysis of the Canadian multicentre osteoporosis study (2018) (25)
- Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario (2021) (24)
- Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension (2017) (23)
- Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. (2015) (23)
- Histomorphometric and Densitometric Changes in the Femora of Spinal Cord Transected Mice (2008) (22)
- Paget’s disease of bone: an osteoimmunological disorder? (2015) (22)
- Gene expression profile in osteoclasts from patients with Paget's disease of bone. (2010) (22)
- Evidence for impaired skeletal load adaptation among Canadian women with type 2 diabetes mellitus: insight into the BMD and bone fragility paradox. (2013) (21)
- Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting (2011) (21)
- Diagnosis and treatment of Paget's disease of bone. (2007) (20)
- Factors influencing the treatment of osteoporosis following fragility fracture (2009) (19)
- Is There Regional Variation in the SF-36 Scores of Canadian Adults? (2002) (19)
- What predicts early fracture or bone loss on bisphosphonate therapy? (2003) (19)
- The burden of illness of osteoporosis in Canada (2011) (19)
- A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab (2020) (19)
- Genetic association study of UCMA/GRP and OPTN genes (PDB6 locus) with Paget's disease of bone. (2012) (19)
- Environmental factors associated with familial or non-familial forms of Paget's disease of bone. (2017) (18)
- Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos) (2019) (18)
- Detection of SQSTM1/P392L post-zygotic mutations in Paget’s disease of bone (2014) (17)
- Alternative splicing in osteoclasts and Paget’s disease of bone (2014) (17)
- Identification of rare genetic variants in novel loci associated with Paget’s disease of bone (2014) (17)
- Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. (2016) (17)
- Use of Phalangeal Bone Mineral Density and Multi-site Speed of Sound Conduction to Monitor Therapy with Alendronate in Postmenopausal Women (2002) (17)
- Direct medical resource utilization associated with osteoporosis‐related nonvertebral fractures in postmenopausal women (2013) (17)
- Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism. (2016) (17)
- The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. (2006) (16)
- Predicting Subsequent Bone Density Response to Intermittent Cyclical Therapy with Etidronate from Initial Density Response in Patients with Osteoporosis (2000) (16)
- Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population (2018) (16)
- Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study (2018) (16)
- Effect of genetic variants of OPTN in the pathophysiology of Paget's disease of bone. (2018) (15)
- Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada (2021) (15)
- Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos). (2016) (15)
- Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice (2016) (15)
- Relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 8 years of denosumab treatment (2015) (14)
- Romosozumab Improves Lumbar Spine Bone Mass and Bone Strength Parameters Relative to Alendronate in Postmenopausal Women: Results From the ARCH Trial. (2021) (13)
- Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study (2006) (13)
- Role of ATF7‐TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease (2013) (13)
- Vertebral Fractures and Morphometric Deformities (2018) (12)
- Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices? (2004) (12)
- Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active‐Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial (2021) (12)
- Antiresorptives: Safety Concerns—Clinical Perspective (2017) (12)
- A comparative trial of risedronate vs. etidronate in the treatment of patients with Paget’s disease of bone (1999) (11)
- Skeletal responses to romosozumab after 12 months of denosumab (2021) (11)
- Oral Corticosteroids in Asthma: A Review of Benefits and Risks (2007) (11)
- Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. (2013) (11)
- Normative bone mineral density z-scores for Canadians aged 16 to 24 years: the Canadian Multicenter Osteoporosis Study. (2010) (11)
- A critical review of brand and generic alendronate for the treatment of osteoporosis (2013) (10)
- Osteoclast Apoptosis in Rheumatic Diseases Characterized by a High Level of Bone Resorption (Osteoporosis, Rheumatoid Arthritis, Myeloma and Pagets Disease of Bone) (2009) (10)
- Comparative effects of densitometric and absolute fracture risk classification systems on projected intervention rates in postmenopausal women. (2007) (10)
- Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. (2001) (10)
- Long-Term Treatment of Postmenopausal Osteoporosis (2021) (10)
- Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget’s disease of bone (2017) (10)
- Low 5-year stability of within-patient ion excretion and urine pH in fasting-morning-urine specimens. (2009) (10)
- The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture (2014) (10)
- Development of a molecular test of Paget's disease of bone. (2016) (9)
- Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone (2013) (9)
- Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting (2011) (9)
- Romosozumab and Teriparatide Effects on Vertebral Cortical Mass, Thickness, and Density in Postmenopausal Women With Low Bone Mineral Density (BMD). (2014) (9)
- Femur geometrical parameters in the pathogenesis of atypical femur fractures (2013) (8)
- Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada (2021) (8)
- Ten years of Denosumab (DMAB) treatment in postmenopausal women with osteoporosis. Results from the FREEDOM Extension trial. (2016) (8)
- Extensive modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial (2020) (7)
- Where’s the break? Critique of radiographic vertebral fracture diagnostic methods (2021) (7)
- ArticleThe Atypical PKC-Interacting Protein p 62 Is an Important Mediator of RANK-Activated Osteoclastogenesis (2004) (7)
- Atypical femur fractures: a survey of current practices in orthopedic surgery (2017) (7)
- Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses. (2014) (7)
- A Meta-Analysis Of Trabecular Bone Score In Fracture Risk Prediction And Its Interaction With Frax (2015) (7)
- Molecular effect of an OPTN common variant associated to Paget's disease of bone (2018) (7)
- Duration‐Dependent Increase of Human Bone Matrix Mineralization in Long‐Term Bisphosphonate Users with Atypical Femur Fracture (2020) (6)
- Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. (2010) (6)
- Normative data for multisite quantitative ultrasound: the Canadian Multicenter Osteoporosis Study. (2014) (6)
- Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients (2021) (6)
- Vertebral Fractures: Which Radiological Criteria Are Better Associated With the Clinical Course of Osteoporosis? (2020) (6)
- Superior Gains in Bone Mineral Density (BMD) and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide (TPTD) in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study (2016) (6)
- Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? (2005) (6)
- Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years (2022) (6)
- Gene-environment interactions in Paget's disease of bone. (2019) (6)
- Heterogeneity in skeletal load adaptation points to a role for modeling in the pathogenesis of osteoporotic fracture. (2014) (5)
- Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study (2021) (5)
- OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results (2013) (5)
- Does Epstein-Barr Virus Infection Contribute to Disease Flares in Rheumatoid Arthritis? (2016) (5)
- Strength at the Lumbar Spine and Hip Improves with Romosozumab Compared with Teriparatide in Postmenopausal Women with Low Bone Mass (2015) (5)
- Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis (2011) (5)
- Ly6Chigh monocytes facilitate transport of Murid herpesvirus 68 into inflamed joints of arthritic mice (2018) (5)
- Modeling‐Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial (2021) (4)
- CAR Technical Standards for Bone Mineral Densitometry Reporting (2010) (4)
- Response to: Comment on: “Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis” (2015) (4)
- BMD Response to Delayed-Release Risedronate 35 Mg Once-A-Week Formulation Taken With or Without Breakfast (2010) (4)
- Metabolic bone diseases: Treating Paget disease: when matters more than how (2009) (4)
- DESCRIPTIVE STUDY OF OSTEOPOROTIC FRACTURES AND HIP FRACTURE RISK EVALUATION OF SUBJECTS WITH PAST MINOR FRACTURES. (2008) (3)
- Bone turnover markers: Defining a therapeutic target. (2016) (3)
- Change in Quantitative Ultrasound-assessed Speed of Sound as a Function of Age in Women and Men and Association With the Use of Antiresorptive Agents: The Canadian Multicentre Osteoporosis Study. (2019) (3)
- Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density (2021) (3)
- A randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates (2016) (3)
- Five-year incident fracture risk assessed by quantitative multisite ultrasound: The Canadian Multicentre Osteoporosis study (2012) (3)
- Poster 6: Duloxetine 60 to 120 mg Once Daily Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain (2009) (3)
- relationship between total hip BMD T-score and incidence of nonvertebral fracture with up to 10 years of Denosumab (DMAB) treatment (2016) (2)
- 67 Denosumab Improves Forearm Densitometric, Geometric and Strength Indices as Measured by QCT in Postmenopausal Women With Low BMD (2009) (2)
- Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial (2010) (2)
- Vertebral Fractures: Which Radiological Criteria Are Better Associated With the Clinical Course of Osteoporosis? (2020) (2)
- Osteoporosis in children: 2002 guidelines do not apply (2003) (2)
- A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerations. (2011) (2)
- Chapter 8 – Paget’s Disease of Bone: Prognosis and Complications (2016) (2)
- Denosumab (DMab) restores cortical bone loss at the 1/3 radius associated with ageing and reduces wrist fracture risk: analyses from the FREEDOM Extension Cross-over Group (2015) (2)
- The Canadian Consensus on Menopause and Osteoporosis - 2002 Update (2002) (2)
- Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip over 8 years of denosumab treatment (2014) (2)
- Prediction of Osteoporotic Fractures in Elderly Individuals: A Derivation and Internal Validation Study Using Healthcare Administrative Data (2021) (2)
- Effects of Denosumab (Dmab) on bone matrix mineralization: results from the phase 3 FREEDOM trial (2016) (2)
- Risedronate demonstrates fracture efficacy in postmenopausal women whether there is a BMD gain or loss during treatment (2006) (2)
- Inhibition of sclerostin with romosozumab in postmenopausal women with low BMD : phase 2 trial results (2013) (2)
- Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. (2015) (2)
- Prevention and treatment of osteoporosis (2003) (2)
- Administration of annual oral high-dose vitamin D to community-dwelling older women in autumn and winter months increases risk of falls and fractures (2010) (1)
- Denosumab Increased BMD of the Lumbar Spine, Total Hip, Femoral Neck, and Trochanter as Measured by QCT in Postmenopausal Women with Osteoporosis (2010) (1)
- Sustained fracture risk reduction over 5 years with risedronate therapy (2001) (1)
- Denosumab treatment for 6 years in postmenopausal women with osteoporosis: The first 3 years of the freedom extension (2012) (1)
- Current use of bone turnover markers in the management of osteoporosis. (2022) (1)
- Denosumab Treatment Is Associated With Progressive Improvements in Cortical Mass and Thickness at the Hip in Regions Relevant to Fracture Protection (2013) (1)
- Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension (2013) (1)
- Denosumab increases total, trabecular, and cortical estimated hip and spine strength in postmenopausal women with osteoporosis (2011) (1)
- Retraction Notice to "Kidney Function and Rate of Bone Loss at the Hip and Spine: The Canadian Multicentre Osteoporosis Study" [Am J Kidney Dis. 55(2):291-299]. (2016) (1)
- Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics". (2016) (1)
- Peripheral quantitative ultrasound for the prediction of fracture over five years: The Canadian Multicentre Osteoporosis Study (CAMOS) (2011) (1)
- Characterizing the Assessment and Management of Vitamin D Levels in Patients with Osteoporosis in Clinical Practice: A Chart Review Initiative (2015) (1)
- Genetic Epidemiology of Paget's Disease of Bone in Eastern Quebec (1999) (1)
- Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial. (2012) (1)
- Efficacy and safety of duloxetine in the treatment of pain associated with knee osteoarthritis (2009) (1)
- A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate. (2015) (1)
- Denosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension (2012) (1)
- Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada (2022) (1)
- Denosumab is associated with progressive improvements in hip cortical mass and thickness (2013) (1)
- Clinical phenotype of adult offspring carriers of the p.Pro392Leu mutation within the SQSTM1 gene in Paget's disease of bone (2020) (1)
- Attenuated clinical and osteoclastic phenotypes of Paget’s disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a rare variant in the DOCK6 gene (2022) (1)
- THU0418 Denosumab Versus Risedronate: Efficacy and Safety in Postmenopausal Women Suboptimally Adherent to Alendronate Therapy in a Randomized Open-Label Study (2013) (1)
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2016): Oral Communication Abstracts (2016) (1)
- Novel Approaches to the Treatment of Osteoporosis (2015) (1)
- Atypical femur fractures: evaluation of femoral stresses and strain using finite element analysis (2015) (0)
- Multisite Ultrasound and Fracture Risk: Findings from the Canadian Multicentre Osteoporosis Study (CaMOS) (2006) (0)
- Review for "Estimation of long-term efficacy of denosumab treatment in postmenopausal women with osteoporosis: a FRAX- and virtual twin-based post hoc analysis from FREEDOM and FREEDOM Extension trials" (2019) (0)
- Corrigendum to “Gene expression profile in osteoclasts from patients with Paget's disease of bone” [Bone 46 (2010) 598–603] (2010) (0)
- Percentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment (2015) (0)
- Grade 1 Vertebral Height Loss is Not Associated with Decreased Quality of Life (2017) (0)
- Discordance between bone mineral density and speed of sound measures of bone: the Canadian Multicentre Osteoporosis study (2014) (0)
- [Comparative study of serum osteocalcin and of the histomorphometric evaluation of iliac biopsy in postmenopausal osteoporosis]. (1984) (0)
- Participation in strenuous sports reduces stance stress at the medial femoral neck in Canadian men and women (2011) (0)
- Extended safety observations from denosumab administration in postmenopausal women from FREEDOM and FREEDOM extension trials (2011) (0)
- articleSafety of bazedoxifene in a randomized , double-blind , placebo-and active-controlled phase 3 study of postmenopausal women with osteoporosis (2015) (0)
- Denosumab Significantly Improves Total, Trabecular, and Cortical Estimated Strength at the Hip and Spine Over the Duration of the FREEDOM Trial (2011) (0)
- Changes in Multisite Quantitative Ultrasound Speed of Sound over Five Years of Follow-Up: the Canadian Multicentre Osteoporosis Study (2015) (0)
- PMS52 REAL-WORLD OUTCOMES AND COST OF MANAGEMENT OF OSTEOPOROTIC FRACTURES IN ONTARIO, CANADA (2019) (0)
- Genetic Association Study of Dickkopf-1 and Sclerostin Genes with Paget Disease of Bone (2013) (0)
- Analysis of cortical bone quality in long-term bisphosphonate users with atypical femur fracture (AFF) (2020) (0)
- Consistency of effect of alendronate in glucocorticoid-induced and postmenopausal osteoporosis (1998) (0)
- The diagnosis of osteoporotic vertebral fractures redux. (2021) (0)
- Strontium ranelate increases the number of patients with improvement in osteoarthritis symptoms compared to placebo in the SEKOIA study (2013) (0)
- Percentage of women achieving non-osteoporotic BMD T-scores at the spine and hip during up to 8 years of denosumab (Dmab) treatment (2015) (0)
- Bone mineral density changes in patients with prior fracture suboptimally treated with a bisphosphonate: results from denosumab (DMAb)/ibandronate and DMAb/risedronate trials (2013) (0)
- Osteoporosis-Related Nonvertebral Fracture Risk Reduction vs. Hitoric Control at Two Years with Risedronate 150mg Once-A-Month (2009) (0)
- Treatment of postmenopausal women with osteoporosis for 5 years with denosumab : two-year results from the FREEDOM trial extension (2011) (0)
- The impact of vitamin D and calcium intake on estimated bone stiffness as assessed by multisite quantitative ultrasound: the Canadian Multicentre Osteoporosis study (2014) (0)
- Screening men for osteoporosis (2007) (0)
- PAPER 153: FACTORS INFLUENCING THE DIAGNOSIS AND THE TREATMENT OF OSTEOPOROSIS FOLLOWING A FRAGILITY FRACTURE (2010) (0)
- Evidence for diminished skeletal load response in women who fracture early vs. those who fracture late in life (2012) (0)
- The association between body mass index and health-related quality of life: data from CaMos, a stratified population study Wilma M. HopmanClaudie BergerLawrence JosephSusan I. Barr • Yongjun GaoJerilynn C. PriorSuzette PoliquinTanveer Towheed • Tassos AnastassiadesCaMos Research Group (2007) (0)
- Hip and vertebral fractures increase mortality rates in Canadians (2009) (0)
- Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial (2020) (0)
- Attenuated clinical and osteoclastic phenotypes of Paget’s disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a rare variant in the DOCK6 gene (2022) (0)
- Response to Dr Lamy and Dr Gonzalez‐Rodriguez (2018) (0)
- Long-Term Safety and Efficacy of Denosumab in Postmenopausal Osteoporosis (2011) (0)
- Clinically meaningful effect of strontium ranelate on knee osteoarthritis symptoms (2012) (0)
- Identification of rare genetic variants in novel loci associated with Paget’s disease of bone (2013) (0)
- Molecular test of Paget's disease of bone in families not linked to SQSTM1 gene mutations (2023) (0)
- The impact of physical activity on estimated bone stiffness as assessed by multisite quantitative ultrasound: the Canadian Multicentre Osteoporosis study (2014) (0)
- SQSTM1/P392L post-zygotic mutations in unrelated patients with Paget's disease of bone (2013) (0)
- Kinetic reconstruction of the cancellous (Cn) and endocortical (Ec) remodelling unit reveals a net positive bone balance (BB) after 12 months of treatment with romosozumab (2021) (0)
- Detection of SQSTM1/P392L post-zygotic mutations in Paget’s disease of bone (2014) (0)
- Supplementary material : Environmental factors associated with familial or non-familial forms of Paget's disease of bone (2017) (0)
- Freedom Trial First-Year Extension: Results from 4 Years of Denosumab Exposure in Women with Postmenopausal Osteoporosis (2010) (0)
- In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate (2014) (0)
- Decline in clinical severity of Paget's disease of bone: Comparison between a contemporary cohort and a historical cohort. (2023) (0)
- PROGRESSIVE IMPROVEMENTS IN CORTICAL MASS AND THICKNESS THROUGHOUT THE HIP WITH DENOSUMAB (DMAB) (2013) (0)
- How adequate are follow up times in prospective studies for estimating 10-year absolute risk of fracture among the elderly? (2010) (0)
- articleLow urine pH and acid excretion do not predict bone fractures or the loss of bone mineral density : a prospective cohort study (2015) (0)
- Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials. (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jacques P. Brown?
Jacques P. Brown is affiliated with the following schools:
